Pathogenic or likely pathogenic variants were identified in 19.5% of triple-negative essential thrombocythemia (TN-ET) patients, correlating with older age and increased prior thrombosis.
Mutations in ASXL1, CBL, EZH2, and ZRSR2 are strongly linked to inferior leukemia-free survival and higher leukemic progression risk.
Age >60 years, history of thrombosis, and cardiovascular risk factors are significant predictors of thrombotic events.
Revised IPSET-thrombosis and ARTS scoring systems effectively stratify thrombotic risk over a 10-year period in TN-ET patients.
